Publications found:
73,128
Sort by:
Global Dialysis Market Report: 2013 Edition
US$ 800.00
... report analyzes the global dialysis market with focus on its segments including: dialysis services, dialysis products, and dialysis drugs. Moreover, the regional market of China is also discussed. Furthermore market ... On the contention front, the global dialysis market is fiercely competitive with a handful of ...
July 2013
55 pages
Competitor Analysis ErbB / Her Receptor Antagonists
US$ 853.00
... /Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody therapy has spurred the discovery and development of efficacy ... with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...
July 2013
168 pages
North America Weight Loss/Obesity Management Market – [Meal Replacements, Slimming Centers, Nutrition & Psychological Consultancy, Treadmill, Ellipticals, Strength Training, Gastric Bypass, Intragastric Balloon System, StomaphyX] – Forecasts to 2017
US$ 3,390.00
... consumers in North America have opened new avenues for the weight management industry. The North American weight loss/obesity management market was worth $104 billion in 2012. The North America weight management market ... leading players in the North American weight management market. Scope of the Report This research report categorizes the North America weight loss/obesity management market into weight loss diets, fitness and ...
July 2013
285 pages
Merck -Suvorexant delayed but no additional studies required is a sigh of relief
US$ 90.00
FDA recently issued a complete response letter to MRK’s Suvorexant. As per the complete response letter, the USFDA will need ... not be approved. We see the launch timelines delayed by atleast 12 to 18 months. In case of the 10mg dose Merck would have to conduct an additional stability study ...
July 2013
1 pages
European Home Healthcare Market By Products (Blood Glucose Meter, ECG, IV Equipment, Nutrition, Wheelchair, Fitness, Heart Rate Monitor, Pregnancy Test Kit), Services (Respiratory Therapy, Rehabilitation Therapy) & Telehealth – Forecasts to 2017
US$ 3,390.00
... Home Telehealth Market Home Telehealth Monitoring Devices Home Teleheath Services Home Healthcare Services Market Rehabilitation Therapy Services Unskilled Care Infusion Therapy Respiratory Therapy European Home Healthcare Market ...
July 2013
303 pages
Competitor Analysis: c-MET/HGF Inhibitors
US$ 394.00
The present Competitive Intelligence Report about Competitor Analysis: c-MET/HGF Inhibitors provides a competitor evaluation in the field of small molecule and ... HGF receptor) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for the treatment of solid tumors as of July 2013. Purchase of the ...
July 2013
57 pages
2013 Worldwide Kidney Dialysis Centers Industry-Industry & Market report
US$ 249.00
The 2013 Worldwide Kidney Dialysis Centers Industry-Industry & Market report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2013 current and 2014 forecast estimates on the size of the industry (sales, ...
July 2013
104 pages
Global API Market Forecast to 2017
US$ 1,400.00
... for growth. In our latest research study, "Global API Market Forecast to 2017", RNCOS analysts identified market dynamics in various important regions to highlight ... landscape. Furthermore, the report elaborates on the High Potency API (HPAPI) market dynamics that represents the fastest growing niche. Overall ...
July 2013
105 pages
Patient-Centricity: Solving the Latest Marketing Puzzle
US$ 595.00
... access patient input. What’s more, there is no broad consensus on patient-centric practices, nor are there standard operating procedures. That is, until now. In Patient-Centricity: Solving the latest marketing ... into how to integrate patient-centricity into the pharma business model. Scope Patient-Centricity: Solving the latest marketing puzzle answers key questions: Patient-centric efforts are moving to the ...
July 2013
-
Physician Views: Do EU Pulmonologists Anticipate Rapid Uptake for GSK’s Seretide-Successor?
US$ 695.00
... can access results from an earlier Physician Views poll of US-based pulmonologist attitudes towards Breo The attitude of European pulmonologists towards usage of a once-daily LABA ... for Relvar in Europe. Purchase Reasons This week's Physician Views poll will specifically ask pulmonologists based in the 5EU countries: What percentage of COPD ...
July 2013
-
Global Gene Therapy Market Analysis
US$ 1,200.00
... to boost the growth. According to RNCOS’ new research report, “Global Gene Therapy Market Analysis”, major focus has been made on the ongoing ... therapy include cardiac conditions, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. ...
June 2013
110 pages
Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
US$ 695.00
... survival (Novartis is seeking to demonstrate this benefit for Tasigna versus Gleevec). However, there would appear to be a limited window of maximum commercial ... expiry in 2015. Set against this backdrop of uncertainty, this week's Physician Views poll will ask US-based oncologists to share their opinions ...
June 2013
-
North American Home Healthcare Market, By Product [Blood Glucose Meter, ECG, IV Equipment, Nutrition, Wheelchair, Fitness, Heart Rate Monitor, Pregnancy Test Kit], Services [Respiratory Therapy, Rehabilitation Therapy] & Telehealth - Forecasts To 2017
US$ 3,390.00
... home health agencies and risk to the safety of home healthcare workers are factors limiting the growth of this market. The U.S. dominated the North American home healthcare market ...
May 2013
271 pages
Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside
US$ 140.00
... drugs) has gained 50% of market share in 16 months of launch showing acceptability of Halozyme’s (HALO) ENHANZE platform (recombinant human hyaluronidase, rHuPH20 use in the ... detail, please read our report released on May 24, 2013, titled, “HyQvia Approval in EU and Upcoming milestones = Upside”.
May 2013
4 pages
Healthcare IT Market By Application [Provider IT (EMR, PACS, CPOE, RIS, CDSS, RCM, Claims Management, Payroll), Payer IT (CRM, Fraud Detection)], Delivery Mode (On-Premises, Web-Based Services & Cloud Computing) & Component – Global Forecasts to 2017
US$ 3,390.00
... technology market by delivery mode, by components, and application. These markets are further broken down into segments and sub-segments. Global Healthcare Information Technology Market, by Application: Global Provider Healthcare Information Technology Market Clinical ...
May 2013
311 pages
Personalized Medicine Market Analysis
US$ 1,200.00
... towards achieving higher goals in the same. According to our new research report, “Personalized Medicine Market Analysis”, the U.S. represents the brightest ... and consolidation has also become a common trend towards greater market presence. Academic and private research institutions as well as small biotech ...
May 2013
90 pages
Competitor Analysis: Thrombolytics & Fibrinolytics
US$ 330.00
The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes ...
May 2013
38 pages
Analysis of Coronary Stent in US
US$ 1,200.00
... , and a severe rise in chronic diseases. According to our report “Analysis of Coronary Stent in US”, reducing the burden of chronic diseases will have a significant ... . The report also provides the existing and future market dynamics of the coronary stent market in US. Further, the report provides a detailed ...
May 2013
45 pages
Para IV Plus Database
US$ 8,000.00
... undisclosed settlement dates, based on available facts. In other words, Para IV Plus is not merely a database but is a tool with in-depth insights for every ... gives list of potential API buyers To a pharma company desirous of banking on the Para IV litigations, this tool will help them strategize their entry ...
May 2013
-
Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value
US$ 595.00
... the company. Ensuring Optimal Medical Affairs Performance: delivering measurable value is an invaluable resource for anyone interested in the evolution, measurement, and management of Medical Affairs – including Medical Affairs directors; Brand ... to ensure that Medical Affairs staff don’t feel alienated) Be aware of the benefits of cloud computing and tablet technology Highlights Key Questions Answered Ensuring Optimal Medical Affairs Performance: delivering ...
May 2013
48 pages
Effective Sales and Marketing Strategies for Drugs with Companion Diagnostics
US$ 595.00
... rethink fundamentally their drug development and marketing strategies. Everyone is a winner with companion diagnostics. ... . Patients benefit from effective treatment and reduced side effects. Payers benefit ... the new market realities and partnership working with wider stakeholder education and integrated sales ...
May 2013
69 pages
Japan Pharma Database
US$ 15,000.00
Pricing: Japan Database: $15,000/- subscription p/a Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets ... reliable Source in public domain 5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas ...
April 2013
-
ENDOCYTE - Small and Powerful Targeted Therapy!
US$ 140.00
Endocyte’s (ECYT) SMDC technology platform and drug pipeline caught investor’s ... our initiation report released on 19th April, 2013 on ECYT titled “Small and Powerful Targeted Therapy!
April 2013
11 pages
Xtandi- The Real Potential and the Astellas Part!
US$ 500.00
Xtandi- The Real Potential and the Astellas Part! Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to ... Although, the clinical profile of Xtandi (steroid free regimen, better safety and efficacy than Zytiga) carries potential to compete with Casodex/Zytiga ...
April 2013
12 pages
Competitor Analysis: Human Growth Hormone (hGH)
US$ 395.00
Product description The Competitive Intelligence Report Human Growth Hormone (hGH) as of April 2013 provides a competitor analysis in the development pipeline of biosimilar versions of somatropin and next generation biobetter/biosuperior hGH products for treatment of growth hormone deficiency (GHD) in ...
April 2013
49 pages
Competitor Analysis: Erythropoiesis Stimulating Agents (ESA)
US$ 650.00
... and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of ...
April 2013
94 pages
Global Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities (2012-2017)
US$ 700.00
... titled ‘Global Irritable Bowel Syndrome Market: Trends and Opportunities (2012-17)’ provides an in depth analysis of IBS market on a global level. The report presents the global market sizing of IBS and ... Sucampo Executive Summary Irritable Bowel Syndrome or IBS is a gastrointestinal disorder in which the colon muscle contracts more readily. The high prevalence of this syndrome could be estimated ...
April 2013
50 pages
Healthcare Decision Support and IBM Watson: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019
US$ 3,800.00
... Research announces that it has published a new study Healthcare Decision Support and IBM Watson Market Shares, Strategy, and Forecasts, Worldwide, ... that are not useful in a particular situation, account for 30% of the costs of healthcare delivery in the US. This is a lot. To have a new system available that ...
March 2013
281 pages
Physician Views: What opportunity beyond the anti-TNFs in rheumatoid arthritis?
US$ 695.00
... RA patients. But is the market opportunity for alternative biologic RA therapies ... these questions, this week's Physician Views poll asks rheumatologists ... what scenario they think would most likely see them increasingly usage of an alternative product in favour of an anti-TNF in RA patients progressing beyond ...
March 2013
-
Multiple Sclerosis Therapeutics Market Analysis By Drug Class (Immunomodulators, Immunosuppressant, Copaxone, Avonex, Gilenya, Tysabri, Betaseron, Tecfidera, Rebif, Ampyra, Aubagio, Extavia, Plegridy, Alemtuzumab, Glatopa, Siponimod, Ocrelizumab, Laquinimod, Zinbryta), By Mode of Administration (Oral, Injectable, Intravenous) And Segment Forecasts To 2024
US$ 5,950.00
... one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in ... high prescription rates & price North America dominated the overall multiple sclerosis therapeutics market with revenue estimates at over 13.0 billion in 2015. ...
March 2013
86 pages
PET Scanner Market in India 2013
US$ 950.00
... a snapshot of the PET scanner market. It begins with an overview of the major macro economic indicators of India which highlights the present economic ... includes competitive benchmarking of the top players operating in the PET scanner market in India. The report also provides brief profiles of the major ...
March 2013
41 pages
UAE IVF Treatment Market Analysis
US$ 600.00
... be prevented. “UAE IVF Treatment Market Analysis” research report gives detailed information on following aspects related to booming IVF treatment market in UAE: Current Market Scenario IVF Treatment Market Potential Treatment cycle & Birth Rate Fertility Treatment Loan ...
March 2013
68 pages
China Hospital Industry Development and Investment Report, 2012-2015
US$ 2,300.00
... , and tumour hospitals as well as their development outlook; development prediction of China hospital industry: status quo of China medical security, boosting urbanization ... major privately-owned specialized hospitals in China, six listed companies that have accessed into the hospital industry, and two foreign ...
March 2013
120 pages
Digital Doctors: Marketing to Online Networks (2nd Edition)
US$ 595.00
... on physician communities – Digital Doctors: Marketing to Online Networks (2nd Edition) – is your definitive guide to the leading online physician networks in both developed and emerging markets: What are ... , Marketing Communications/Channels, Merck Sven Awege, pharma digital consultant (clients have included Eli Lilly and Doctors.net.uk) Tim Ringrose, CEO of Doctors.net ...
March 2013
52 pages
Global Coronary Stent Market Report – 2013 Edition
US$ 800.00
... due to intensity and rate of increase of the disease. The coronary stents market has witnessed growth as well as decline phases in its journey. ... Japan and Europe/Rest of the world. The competition in the global coronary stent market is intense with few large players viz. Abbott Laboratories, Medtronic ...
February 2013
58 pages
HIV - KOL Insight and Consensus Outlook Modules
US$ 7,495.00
... FirstWord research is provided in two comprehensive modules: The KOL Insight: HIV module provides a complete review underpinned by exclusive in-depth interviews with ... Protease inhibitors CCR5 inhibitor Expert Opinion for Real World Insights The data and analysis in the report is enriched through the ...
February 2013
183 pages
SYMBIO - Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!
US$ 140.00
... FY13 (¥1,927m de-growth of 1.4%) and discontinuation of TREAKISYM for refractory/relapsed aggressive non-Hodgkin’s Lymphoma (NHL) brought down SymBio pharma (4582 ... , please read our report released on 22nd February 2013 on SymBio titled “Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!”
February 2013
4 pages
The Long Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living
US$ 3,196.00
... . These twin challenges are addressed in The Long-Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living The report ... the Marketplace Competitors and Competitive Analysis Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are ...
February 2013
-
DR REDDY’S LAB - Growth to Slow Down on Higher Base, Margins to Remain Under Pressure
US$ 140.00
Dr Reddy’s Q3FY13 result was below our estimates as ... XL, ramp up of Fondaparinux (hospital segment) and Amoxil. We expect Dr. Reddy may participate in Vidaza opportunity which is due any time as an API ... US and Russia. We reiterate our market perform rating on Dr Reddy’s and retain out target price of Rs.1929.
February 2013
7 pages
